Supplementary Materials

Supplementary Material for:

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy

Serena Pellegatta, Barbara Savoldo, Natalia Di Ianni, Cristina Corbetta, Yuhui Chen, Monica Patané, Chuang Sun, Bianca Pollo, Soldano Ferrone, Francesco DiMeco, Gaetano Finocchiaro, Gianpietro Dotti*

*Corresponding author. Email: gdotti{at}

Published 28 February 2018, Sci. Transl. Med. 10, eaao2731 (2018)
DOI: 10.1126/scitranslmed.aao2731

This PDF file includes:

  • Fig. S1. Normal brain vessels do not express CSPG4.
  • Fig. S2. CSPG4.CAR is expressed in T cells.
  • Fig. S3. CSPG4.CAR-Ts prolonged the survival of mice injected with BT275-NS and BT462-NS.
  • Fig. S4. CSPG4.CAR-Ts controlled tumor growth in the U87-MG xenograft model.
  • Fig. S5. CSPG4.CAR encoding either CD28 or CD28/4-1BB showed lower antitumor activity than CSPG4.CAR encoding 4-1BB.
  • Fig. S6. CSPG4.CAR encoding either CD28 or CD28/4-1BB costimulatory endodomains showed limited antitumor activity in vivo.
  • Fig. S7. CSPG4.CAR-Ts encoding either CD28 or CD28 and 4-1BB persisted for less than 5 days.
  • Fig. S8. GBM-NS–derived gliomas recurring in vivo retained CSPG4 expression.
  • Fig. S9. GBM-NS up-regulated PD-L1 in response to IFN-γ.
  • Fig. S10. HER-2 and IL-13Rα2 expression is not up-regulated in GBM-NS in xenograft models.
  • Table S1. GBM characterization based on CSPG4 expression and molecular subtypes.

[Download PDF]